ViiV, Janssen to take on Gilead with single-pill HIV medicine
This article was originally published in Scrip
Executive Summary
ViiV Healthcare and Johnson and Johnson are teaming up to develop a single-tablet HIV treatment, hoping that by joining forces they can take on HIV market leader Gilead Sciences.